{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=36",
    "query": {
      "intervention": "therapy",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 83846,
    "total_pages": 8385,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=therapy&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T20:16:23.349Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02661373",
      "title": "First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "SJ733",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-03-01",
      "completion_date": "2018-03-09",
      "has_results": false,
      "last_update_posted_date": "2019-01-02",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661373"
    },
    {
      "nct_id": "NCT02649673",
      "title": "LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "LCL161",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Pegylated GCSF (PEG-GCSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2016-03-23",
      "completion_date": "2021-07-30",
      "has_results": false,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 3,
      "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02649673"
    },
    {
      "nct_id": "NCT00080873",
      "title": "Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Neuroblastoma",
        "Oral Complications",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Traumeel S",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "3 Years to 25 Years"
      },
      "enrollment_count": 195,
      "start_date": "2004-04",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2016-01-07",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00080873"
    },
    {
      "nct_id": "NCT00804973",
      "title": "Study in Participants With Acute Migraines Headaches",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine Headache"
      ],
      "interventions": [
        {
          "name": "LY2590443",
          "type": "DRUG"
        },
        {
          "name": "Placebo injection",
          "type": "DRUG"
        },
        {
          "name": "Sumatriptan",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2008-11",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2020-05-19",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 19,
      "location_summary": "Beverly Hills, California • Chula Vista, California • Fresno, California + 16 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00804973"
    },
    {
      "nct_id": "NCT05660369",
      "title": "CARv3-TEAM-E T Cells in Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Malignant Glioma",
        "Recurrent Glioblastoma",
        "Recurrent Glioma"
      ],
      "interventions": [
        {
          "name": "CARv3-TEAM-E T cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marcela V. Maus, M.D.,Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-03-22",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660369"
    },
    {
      "nct_id": "NCT02465983",
      "title": "Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "CART-meso-19 T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-05",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465983"
    },
    {
      "nct_id": "NCT02261883",
      "title": "Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Persistent Pulmonary Hypertension of the Newborn"
      ],
      "interventions": [
        {
          "name": "IV Remodulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Hour",
        "maximum_age": "14 Days",
        "sex": "ALL",
        "summary": "1 Hour to 14 Days"
      },
      "enrollment_count": 42,
      "start_date": "2015-07-29",
      "completion_date": "2023-05-17",
      "has_results": true,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02261883"
    },
    {
      "nct_id": "NCT01783054",
      "title": "Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma Pancreas"
      ],
      "interventions": [
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Genetic Expression",
          "type": "GENETIC"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2012-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-03-08",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01783054"
    },
    {
      "nct_id": "NCT03521154",
      "title": "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer (Stage III)"
      ],
      "interventions": [
        {
          "name": "Osimertinib 80mg/40mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Osimertinib 80mg/40mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 216,
      "start_date": "2018-07-19",
      "completion_date": "2027-10-29",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Atlanta, Georgia • Florham Park, New Jersey + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Florham Park",
          "state": "New Jersey"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03521154"
    },
    {
      "nct_id": "NCT02865005",
      "title": "Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone 5.0% Gel (SEEGPharm)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Dapsone 5.0% Gel (Allergan)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seegpharm S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 2361,
      "start_date": "2016-02",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-20",
      "last_synced_at": "2026-10-22T20:16:23.349Z",
      "location_count": 35,
      "location_summary": "Encino, California • Fullerton, California • La Mesa, California + 29 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02865005"
    }
  ]
}